Skip to main content
. Author manuscript; available in PMC: 2012 Aug 1.
Published in final edited form as: Clin Cancer Res. 2011 Jun 20;17(15):4987–4995. doi: 10.1158/1078-0432.CCR-11-0207

Fig. 1.

Fig. 1

Purification of T, B cells from 4T1 TDLN and the phenotype of these cells post in vitro activation and expansion. Unfractionated TDLN cells prepared from freshly harvested 4T1 TDLNs and the purified TDLN B cells and T cells were double-stained with FITC-anti-CD3 and PE-anti-CD19 (Day 0). Activated and expanded cells were double stained similarly (Day 4). Data are representative of three experiments performed.